Supplementary Figure S5 from A Phase I Study of Acapatamab, a Half-life Extended, PSMA-Targeting Bispecific T-cell Engager for Metastatic Castration-Resistant Prostate Cancer
Key points are not available for this paper at this time.
Abstract
Pharmacokinetics of acapatamab
AI에게 질문
Like
Bookmark
Share
View Full Paper
AI에게 질문
Like
Bookmark
Share
View Full Paper
Supplementary Figure S5 from A Phase I Study of Acapatamab, a Half-life Extended, PSMA-Targeting Bispecific T-cell Engager for Metastatic Castration-Resistant Prostate Cancer | Synapse